Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 462 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Abramson Cancer Center at Penn Medicine Clear all
Completed No phase listed Observational

Vape Use Among Younger & Older Smokers

NCT07214168
View directory record Official record
Conditions
Smoking Cigarette, Smoking Behaviors, Vaping, Vaping Behaviors
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

NCT06822049
View directory record Official record
Conditions
Remote vs. In-Person, Remote Visits, In-person Visits
Interventions
Combination Nicotine Replacement Therapy (patch and lozenge)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

NCT04854304
View directory record Official record
Conditions
Breast Diseases
Interventions
Fast Breast Abbreviated Magnetic Renounce Imaging
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional

Cigar Packaging Study

NCT04605874
View directory record Official record
Conditions
Smoking
Interventions
Package Quantity (cigarillos)
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 13, 2026, 7:21 PM EDT
Enrolling by invitation No phase listed Observational

Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

NCT02471170
View directory record Official record
Conditions
Pancreatic Diseases
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2035
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional Results available

Mailed FIT Outreach 2022

NCT05341622
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer
Interventions
Differentiated Box, Standard Mail, Text, No Text, Reminder, No Reminder
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 74 Years
Enrollment
5,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional Results available

Lung Cancer Screening Eligibility Assessment

NCT06133816
View directory record Official record
Conditions
Lung Cancer
Interventions
Framed Introductory Message A, Framed Introductory Message B, Framed Introductory Message C, Framed Tobacco Use Message A, Framed Tobacco Use Message B, Financial Incentive
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
6,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 13, 2026, 7:21 PM EDT
Active, not recruiting No phase listed Observational

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

NCT06870617
View directory record Official record
Conditions
Geriatric Assessment, Advanced Cancer, Toxicity
Interventions
Practical Geriatric Assessment, Correlation of body composition PGA and step count with outcomes
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
70 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Princeton, New Jersey • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Phase 2 Interventional Results available

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

NCT03087760
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 13, 2026, 7:21 PM EDT
Terminated Phase 1 Interventional

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

NCT00915694
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
nelfinavir mesylate, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 13, 2026, 7:21 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

NCT03400254
View directory record Official record
Conditions
Breast Cancer
Interventions
Hydroxychloroquine (HCQ), Gedatolisib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 13, 2026, 7:21 PM EDT
Enrolling by invitation Not applicable Interventional

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

NCT06578637
View directory record Official record
Conditions
FAP, Familial Adenomatous Polyposis
Interventions
R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B)
Dietary Supplement
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Recruiting Phase 2 Interventional

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT04523857
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches

NCT04812795
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Culturally tailored anti-smoking messages, Non-culturally tailored interventions
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
2,214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Phase 2 Interventional Results available

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

NCT00783367
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions
Lenalidomide, Dexamethasone, Rituximab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Early Phase 1 Interventional

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

NCT01396200
View directory record Official record
Conditions
Myeloma
Interventions
Hydroxychloroquine, Rapamycin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 13, 2026, 7:21 PM EDT
Active, not recruiting No phase listed Observational

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

NCT02530008
View directory record Official record
Conditions
Women With Suspected or Confirmed Recurrent Breast Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Withdrawn Phase 1 Interventional

PDT Plus Vitamin D3 for Anal Dysplasia

NCT02698293
View directory record Official record
Conditions
Anal Dysplasia, Carcinoma in Situ
Interventions
Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure

NCT05157048
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Charcoal-filtered cigarette, Non-charcoal filtered cigarette
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 13, 2026, 7:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women

NCT05499520
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Culturally Tailored Anti-Smoking Messages
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
2,591 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 13, 2026, 7:21 PM EDT
Completed No phase listed Observational

Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer

NCT01153282
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 13, 2026, 7:21 PM EDT
Recruiting Early Phase 1 Interventional

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

NCT07278986
View directory record Official record
Conditions
Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies
Interventions
CYTALUX™ (pafolacianine), 1788 4K Camera System with Advanced Imaging Modality
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 13, 2026, 7:21 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

NCT03140670
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RUCAPARIB
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 13, 2026, 7:21 PM EDT